Precipio Inc (PRPO)

[alphaInvestor2]

Mr. Kinnon concluded, “Since the start of the quarter, we accelerated the pace of MX-ICP commercialization, launching three new liquid biopsy diagnostic tests and panels for cancer monitoring and precision medicine, including assays for the most common cancers such as lung cancer and colon cancer. Early in the quarter, we launched our ICEme(TM) Mutation Enrichment Kits for cancer research, making them available commercially to researchers worldwide. A few days later we announced a new pilot study with four leading biopharmaceutical firms designed to validate the accuracy and utility of using MX-ICP-based liquid biopsies to guide and monitor cancer clinical trials. We also presented data at a scientific meeting that reported successful results from a joint project with Amgen to detect actionable mutations in colorectal cancer patients. Importantly, during the quarter we announced our first commercial MX-ICP license--for both clinical and research applications. We also have recently kicked off a new marketing initiative with Google that we expect to help catapult our visibility in the liquid biopsy space. Overall, we are very pleased with the increasing momentum we are achieving with MX-ICP. And with our new streamlined structure, we now can focus our full resources and energies on commercializing this technology whose versatility and ease of use are in sync with the needs of the emerging high growth market for liquid biopsies.” TBIO$